Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198008 | 0.91 | L3MBTL1 (0.67) | PPARAL3MBTL1MMP2PARP10LMNA | |
| Hydrochloric Acid SCHEMBL25375206 | 0.90 | L3MBTL1 (0.65) | PPARAL3MBTL1MMP2LMNALTA4H | |
| SCHEMBL5811176 | 0.85 | GAA (0.70) | PPARAL3MBTL1GAAPARP10MAPT | |
| SCHEMBL24348096 | 0.84 | MAPT (0.51) | PPARAL3MBTL1GAAMAPTLMNA | |
| SCHEMBL21991829 | 0.83 | PPARA (0.62) | PPARAL3MBTL1GAAMMP2MAPT | |
| SCHEMBL38710 | 0.83 | ALOX15 (0.55) | PPARAGAAMAPTSRD5A2TSHR | |
| SCHEMBL12099337 | 0.82 | PPARA (0.56) | PPARAL3MBTL1LMNANPC1RAB9A | |
| SCHEMBL11592057 | 0.81 | L3MBTL1 (0.58) | L3MBTL1GAAMAPTLMNAMAPK1 | |
| SCHEMBL16245586 | 0.81 | PPARA (0.63) | PPARAL3MBTL1GAANPC1RAB9A | |
| SCHEMBL2234098 | 0.80 | PKM (0.69) | PPARAL3MBTL1MMP2MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022063549-A1 | ACTIVE SUBSTANCES AND DRUGS FOR THERAPY OF VIRAL DISEASES, PARTICULARLY CORONA INFECTIONS, MORE PARTICULARLY COVID-19 | CREATIVE THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | WO | disclosed |
| EP-2758367-B1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | DoubleHill GmbH (DE) | 2015-11-18 | — | — | EP | disclosed |
| US-8426390-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426390-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| WO-2013041204-A1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | 2LUTION GmbH (DE) | 2013-03-28 | — | — | WO | disclosed |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8034797-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-8034797-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN PHARMA GMBH (CH) | 2010-09-16 | — | — | US | disclosed |
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN PHARMA GMBH (CH) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | PPARA 2387/4885L3MBTL1 1076/4885GAA 490/4885 |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | PPARA 2387/4885L3MBTL1 1076/4885GAA 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.